The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results.
Hanno Riess
Consultant or Advisory Role - Celgene; Merck; Roche; Sanofi
Jean-Luc Van Laethem
No relevant relationships to disclose
Uwe Marc Martens
No relevant relationships to disclose
Volker Heinemann
No relevant relationships to disclose
Patrick Michl
No relevant relationships to disclose
Marc Peeters
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Research Funding - Bayer
David Van Brummelen
No relevant relationships to disclose
Colin D. Weekes
No relevant relationships to disclose
Svein Dueland
No relevant relationships to disclose
Wolff H. Schmiegel
No relevant relationships to disclose
Marius Giurescu
Employment or Leadership Position - Bayer
Vittorio Luigi Garosi
Employment or Leadership Position - Bayer
Anke Schulz
Employment or Leadership Position - Bayer
Henrik Seidel
Employment or Leadership Position - Bayer
Barrett H. Childs
Employment or Leadership Position - Bayer
Michael Teufel
Employment or Leadership Position - Bayer